MUMBAI, India & NAPLES, Florida, USA, June 3, 2026
Lupin Limited and its alliance partner Natco Pharma have announced a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approval of Natco’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. The approval enables the companies to market a generic version of Halaven® (eribulin mesylate), originally developed by Eisai, in the United States. The development strengthens both companies’ oncology portfolios while expanding access to a critical cancer treatment for patients battling advanced and metastatic cancers. As healthcare systems continue to seek cost-effective treatment options, the approval is expected to improve availability of an important chemotherapy product used in the management of difficult-to-treat malignancies.
U.S. FDA Approval Expands Access to Oncology Treatment
The newly approved Eribulin Mesylate Injection has been confirmed as bioequivalent to the reference listed drug Halaven® Injection, meeting all regulatory standards required by the FDA for safety, quality, and therapeutic equivalence. The medicine is indicated for the treatment of adults with metastatic breast cancer who have previously received at least two chemotherapy regimens for metastatic disease. It is also approved for patients with unresectable or metastatic liposarcoma who have undergone prior treatment with an anthracycline-containing regimen.
These patient populations often have limited treatment options after disease progression, making access to additional therapeutic alternatives particularly important. The approval reinforces the growing role of high-quality generic oncology medicines in improving patient access to life-extending therapies while helping reduce treatment costs across healthcare systems.
Strengthening Lupin and Natco’s Oncology Portfolio
Advertisement
The FDA approval represents another strategic achievement for the longstanding collaboration between Lupin and Natco Pharma, both of which have established strong positions in the global generic pharmaceutical market. By adding Eribulin Mesylate Injection to their portfolio, the companies further strengthen their presence in the specialized oncology segment, an area experiencing increasing demand worldwide. According to industry data, the reference product Halaven® generated approximately USD 43.7 million in annual U.S. sales for the twelve-month period ending April 2026, highlighting the commercial significance of the product category.
The approval also reflects the companies’ continued investment in complex injectable generics, a segment that requires advanced manufacturing capabilities, rigorous quality controls, and extensive regulatory expertise. Such approvals contribute to expanding treatment availability while fostering greater competition in the oncology marketplace.
Supporting Affordable Cancer Care Through Generic Innovation
Cancer remains one of the leading causes of mortality globally, and the availability of affordable treatment options continues to be a critical healthcare priority. Generic medicines play an increasingly important role in ensuring that life-saving therapies reach a broader patient population without compromising quality or effectiveness. Lupin and Natco’s approved Eribulin Mesylate Injection provides healthcare providers with an additional treatment option for managing advanced breast cancer and liposarcoma, supporting efforts to improve patient access and healthcare sustainability.
The approval also underscores Lupin’s broader commitment to expanding its portfolio across key therapeutic areas, including oncology, respiratory diseases, cardiovascular conditions, diabetes, infectious diseases, and women’s health. With a global footprint spanning more than 100 markets and extensive manufacturing and research capabilities, Lupin continues to pursue growth through innovation, regulatory excellence, and strategic partnerships. The latest FDA approval highlights the company’s ongoing focus on delivering high-quality, affordable medicines that address critical patient needs across global healthcare markets.
Source: Lupin, Natco Pharma press release
